Zhongying Mo currently serves as a Senior Principal Scientist at Bristol Myers Squibb, where he plays a pivotal role in advancing the field of drug discovery through his expertise in protein degraders. With a passion for innovative drug hunting, Zhongying is at the forefront of...
Zhongying Mo currently serves as a Senior Principal Scientist at Bristol Myers Squibb, where he plays a pivotal role in advancing the field of drug discovery through his expertise in protein degraders. With a passion for innovative drug hunting, Zhongying is at the forefront of identifying and validating novel protein degraders, leveraging high-throughput screening (HTS) methodologies and phenotypic/genetic approaches to uncover new therapeutic avenues. His work is instrumental in elucidating the mechanisms of action (MoA) of both clinical and preclinical drugs, ensuring that promising candidates are not only effective but also safe for patient use.
Zhongying's extensive background in protein chemistry and cell biology enables him to navigate the complexities of protein folding and misfolding, which are critical factors in drug efficacy and safety. His proficiency in biophysics and advanced techniques such as fluorescence microscopy and phage display allows him to visualize and manipulate protein interactions at a molecular level, facilitating the development of targeted therapies. Additionally, his experience in biomarker selection is vital for the identification of patient populations that will benefit most from novel treatments.
As a leader in his field, Zhongying is not only focused on scientific discovery but also on fostering collaboration and innovation within his team. His management skills ensure that projects progress efficiently while maintaining a high standard of scientific rigor. With a commitment to transforming the landscape of medicine, Zhongying Mo continues to contribute significantly to Bristol Myers Squibb's mission of delivering transformative therapies to patients worldwide.
